24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ALIMLIEVA 500 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ALIMLIEVA 500 MG |
|---|---|
| Composition | Pemetrexed Injection IP 500 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) is a prescription anticancer medicine containing Pemetrexed 500 mg, a chemotherapy agent widely used in the treatment of certain lung cancers and malignant pleural mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and multiplication.
Cancer cells grow and divide rapidly, requiring large amounts of folate-dependent enzymes for survival. Pemetrexed blocks several key enzymes involved in the synthesis of nucleic acids, thereby slowing cancer cell growth and promoting cancer cell death. This targeted action helps control tumor progression and improve treatment outcomes.
ALIMLIEVA 500 MG is commonly prescribed for patients with Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma, either as a single agent or in combination with other anticancer medicines such as platinum-based chemotherapy. It may also be used as maintenance therapy in eligible patients to help delay disease progression.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
ALIMLIEVA 500 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 500 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with regular blood tests and clinical monitoring to minimize side effects and optimize treatment outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 500 MG remains an important medicine in modern cancer care.
ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) is primarily used in the treatment and management of specific cancers.
The medicine is widely used in advanced or metastatic non-squamous NSCLC.
Pemetrexed may be prescribed as maintenance treatment after initial chemotherapy.
The medicine is commonly used in combination with platinum-based chemotherapy for mesothelioma treatment.
Doctors may recommend Pemetrexed as part of comprehensive thoracic oncology treatment plans.
The medicine is frequently administered alongside other anticancer agents.
Pemetrexed helps slow disease progression and improve treatment outcomes.
The medicine is incorporated into internationally recognized cancer treatment regimens.
Pemetrexed belongs to a class of medicines known as Antifolate Anticancer Agents.
ALIMLIEVA works by:
This mechanism helps control cancer development and supports effective disease management.
Like all medicines, ALIMLIEVA 500 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported.
Digestive discomfort may occur during treatment.
Reduced appetite may affect nutritional intake.
The medicine may decrease white blood cells, red blood cells, and platelet counts.
Inflammation or ulcers in the mouth may develop.
Some patients may experience mild to moderate skin reactions.
Digestive disturbances may occur during therapy.
Some individuals may experience constipation.
Lower white blood cell counts may increase susceptibility to infections.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the condition being treated.
Dosage is generally calculated according to body surface area.
Renal function plays an important role in dosage planning.
Regular monitoring helps guide treatment decisions.
Concurrent chemotherapy medicines may influence treatment schedules.
Before starting treatment, inform your doctor if you have:
Patients receiving Pemetrexed are typically advised to take:
These supportive treatments help reduce the risk of certain side effects.
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.
Pemetrexed is an antifolate chemotherapy medicine that blocks enzymes required for cancer cell growth and replication.
Yes. Pemetrexed is a chemotherapy medicine belonging to the antifolate class.
These supplements help reduce the risk and severity of certain treatment-related side effects.
Yes. It is commonly prescribed as maintenance therapy in eligible NSCLC patients.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Kidney function is an important consideration during Pemetrexed therapy and should be monitored regularly.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.